Reported results
- Total revenue for the third quarter of 2026 was $221 million, up 13% year-over-year.
- GAAP gross margin was 71.5% and Non-GAAP gross margin was 71.9% for the quarter.
- GAAP operating expenses were $155 million, compared to Non-GAAP operating expenses of $137 million.
- GAAP net income / (loss) was ($5) million, while Non-GAAP net income / (loss) was $15 million.
- Non-GAAP adjusted EBITDA was $38 million, with a Non-GAAP adjusted EBITDA margin of 17.3%.
- Ending cash balance was $80 million as of September 30, 2026.
Guidance
- For fiscal year 2026, the Company expects total revenue of approximately $862 million, including approximately $789 million of surgical revenue and approximately $73 million of EOS revenue.
- For fiscal year 2026, total revenue growth is expected to be approximately 13% and surgical revenue growth is expected to be approximately 15%.
- For fiscal year 2026, the Company expects adjusted EBITDA of approximately $137 million.
- For fiscal year 2026, the Company expects approximately $10 million of free cash flow.
Price and volatility reaction
The stock moved -38.1% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -15.7 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 11.37 | 2026-10-29 |
| Close after release | 7.04 | 2026-10-30 |
| Realised move | -38.1% | close to close |
| 30d ATM IV change | -15.7 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.
